Cited by 122Regulation of Appetite and ObesityPharmacology and Obesity TreatmentAdipokines, Inflammation, and Metabolic Diseases

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options

Fani, L, Bak, S, Delhanty, P, van Rossum, E F C, van den Akker, E L T·2014·International Journal of Obesity

DOI 10.1038/ijo.2013.80

Open this paper in CoChat — free account

Abstract

Obesity is one of the greatest public health challenges of the 21st century. Obesity is currently responsible for ∼0.7-2.8% of a country's health costs worldwide. Treatment is often not effective because weight regulation is complex. Appetite and energy control are regulated in the brain. Melanocortin-4 receptor (MC4R) has a central role in this regulation. MC4R defects lead to a severe clinical phenotype with lack of satiety and early-onset severe obesity. Preclinical research has been carried out to understand the mechanism of MC4R regulation and possible effectors. The objective of this study is to systematically review the literature for emerging pharmacological obesity treatment options. A systematic literature search was performed in PubMed and Embase for articles published until June 2012. The search resulted in 664 papers matching the search terms, of which 15 papers remained after elimination, based on the specific inclusion and exclusion criteria. In these 15 papers, different MC4R agonists were studied in vivo in animal and human studies. Almost all studies are in the preclinical phase. There are currently no effective clinical treatments for MC4R-deficient obese patients, although MC4R agonists are being developed and are entering phase I and II trials.

Integrity signals

Registry

Crossref · 10.1038/ijo.2013.80

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Interacting Appetite-Regulating Pathways in the Hypothalamic Regulation of Body Weight
Kalra, S. P., Dube, M. G., Pu, S., Xu, B., Horváth, T. L., & Kalra, P. S. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.1.0357 · Cited by 1,564
The economic burden of obesity worldwide: a systematic review of the direct costs of obesity
Withrow, D., & Alter, D. A. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00712.x · Cited by 1,083
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
The FDA's Assessment of Two Drugs for Chronic Weight Management
Colman, E., Golden, J., Roberts, M., Egan, A., Weaver, J., & Rosebraugh, C. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1211277 · Cited by 342
Gene-environment interaction and obesity
Qi, L., & Cho, Y. A. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2008.00128.x · Cited by 280
Social Position, Psychological Stress, and Obesity: A Systematic Review
Moore, C. J., & Cunningham, S. A. (2012) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2011.12.001 · Cited by 242
Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques
Kievit, P., Halem, H., Marks, D. L., Dong, J. Z., Glavas, M. M., Sinnayah, P., Pranger, L., Cowley, M. A., Grove, K. L., & Culler, M. D. (2013) · Diabetes · doi:10.2337/db12-0598 · Cited by 231
Targeting melanocortin receptors as potential novel therapeutics
Getting, S. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.022 · Cited by 194
A Novel Selective Melanocortin-4 Receptor Agonist Reduces Food Intake in Rats and Mice without Producing Aversive Consequences
Benoit, S. C., Schwartz, M. W., Lachey, J. L., Hagan, M. M., Rushing, P. A., Blake, K. A., Yagaloff, K. A., Kurylko, G., Franco, L., Danhoo, W., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-09-03442.2000 · Cited by 178
Sympathetic Response to Insulin Is Mediated by Melanocortin 3/4 Receptors in the Hypothalamic Paraventricular Nucleus
Ward, K. R., Bardgett, J. F., Wolfgang, L., & Stocker, S. D. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.160671 · Cited by 118

Flagged first, then by citations

Show all 33 references

Research works printed but not linked: 1

Raun K, Conde-Frieboes KW, Sensfuss U, Wulff BS . A long acting, selective MC4 receptor agonist effectively reduces appetite and bodyweight in diet induced obese rats. Obes Rev 2011; 12: 279.

Sorted by citations

Melanocortin-4 receptor–regulated energy homeostasis
Krashes, M. J., Lowell, B. B., & Garfield, A. S. (2016) · Nature Neuroscience · doi:10.1038/nn.4202 · Cited by 372
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
Collet, T.-H., Dubern, B., Mokrosinski, J., Connors, H., Keogh, J. M., Mendes de Oliveira, E., Henning, E., Poitou-Bernert, C., Oppert, J.-M., Tounian, P., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.015 · Cited by 302
Gut-Brain Cross-Talk in Metabolic Control
Clemmensen, C., Müller, T. D., Woods, S. C., Berthoud, H., Seeley, R. J., & Tschöp, M. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.025 · Cited by 309
Pursuit of a perfect insulin
Zaykov, A. N., Mayer, J. P., & DiMarchi, R. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.36 · Cited by 294
Rare Genetic Forms of Obesity: Clinical Approach and Current Treatments in 2016
Huvenne, H., Dubern, B., Clément, K., & Poitou, C. (2016) · Obesity Facts · doi:10.1159/000445061 · Cited by 302
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Srivastava, G., & Apovian, C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0300-4 · Cited by 232
Genetic and Epigenetic Causes of Obesity
Thaker, V. (2017) · American Academy of Pediatrics eBooks · doi:10.1542/9781581109405-genetic · Cited by 223
Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment
Kühnen, P., Krude, H., & Biebermann, H. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.12.002 · Cited by 196
RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals
Chen, K. Y., Muniyappa, R., Abel, B. S., Mullins, K. P., Staker, P., Brychta, R. J., Zhao, X., Ring, M., Psota, T. L., Cone, R. D., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4024 · Cited by 174
Hunger and Satiety Mechanisms and Their Potential Exploitation in the Regulation of Food Intake
Amin, T., & Mercer, J. G. (2016) · Current Obesity Reports · doi:10.1007/s13679-015-0184-5 · Cited by 169
The Epigenetic Connection Between the Gut Microbiome in Obesity and Diabetes
Sharma, M., Li, Y., Stoll, M. L., & Tollefsbol, T. O. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2019.01329 · Cited by 156
Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss
Christoffersen, B. Ø., Sanchez‐Delgado, G., John, L. M., Ryan, D. H., Raun, K., & Ravussin, E. (2022) · Obesity · doi:10.1002/oby.23374 · Cited by 142
“Several MC4R agonists failed in the clinic because of increased blood pressure or lack of efficacy combined with hyperpigmentation owing to off- target activity on MC1R (67,68).”
Background
Genetic and epigenetic control of metabolic health
Schwenk, R. W., Vogel, H., & Schürmann, A. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.09.002 · Cited by 135
Latest approaches for the treatment of obesity
Jackson, V. M., Breen, D. M., Fortin, J.-P., Liou, A., Kuzmiski, J. B., Loomis, A. K., Rives, M.-L., Shah, B., & Carpino, P. A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1044966 · Cited by 132
A comprehensive diagnostic approach to detect underlying causes of obesity in adults
van der Valk, E. S., van den Akker, E. L. T., Savas, M., Kleinendorst, L., Visser, J. A., van Haelst, M. M., Sharma, A. M., & van Rossum, E. F. C. (2019) · Obesity Reviews · doi:10.1111/obr.12836 · Cited by 138
Pediatric obesity: Current concepts
Greydanus, D. E., Agana, M. G., Kamboj, M. K., Shebrain, S., Soares, N. S., Eke, R., & Patel, D. R. (2018) · Disease-a-Month · doi:10.1016/j.disamonth.2017.12.001 · Cited by 104
The regulation of PKA signaling in obesity and in the maintenance of metabolic health
London, E., & Stratakis, C. A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108113 · Cited by 99
Converging Relationships of Obesity and Hyperuricemia with Special Reference to Metabolic Disorders and Plausible Therapeutic Implications
Gong, M., Wen, S., Nguyen, T., Wang, C., Jin, J., & Zhou, L. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s232377 · Cited by 95
Dual melanocortin‐4 receptor and GLP‐1 receptor agonism amplifies metabolic benefits in diet‐induced obese mice
Clemmensen, C., Finan, B., Fischer, K., Tom, R. Z., Legutko, B., Sehrer, L., Heine, D., Grassl, N., Meyer, C. W., Henderson, B., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404508 · Cited by 89
Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016
Ericson, M. D., Lensing, C. J., Fleming, K. A., Schlasner, K. N., Doering, S. R., & Haskell‐Luevano, C. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.03.020 · Cited by 91
The impact of probiotic supplementation during pregnancy on DNA methylation of obesity-related genes in mothers and their children
Vähämiko, S., Laiho, A., Lund, R., Isolauri, E., Salminen, S., & Laitinen, K. (2018) · European Journal of Nutrition · doi:10.1007/s00394-017-1601-1 · Cited by 77
Targeting the central melanocortin system for the treatment of metabolic disorders
Sweeney, P., Gimenez, L. E., Hernández, C. C., & Cone, R. D. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00855-y · Cited by 71
Genetics and epigenetics in the obesity phenotyping scenario
Trang, B. K., & Grant, S. F. A. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09804-6 · Cited by 74
Rare genetic forms of obesity: From gene to therapy
Clément, K., Mosbah, H., & Poitou, C. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.113134 · Cited by 57
Biased signaling initiated by agouti-related peptide through human melanocortin-3 and -4 receptors
Zhao, Y., & Tao, Y. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.05.008 · Cited by 49
Neuroendocrinological and Epigenetic Mechanisms Subserving Autonomic Imbalance and HPA Dysfunction in the Metabolic Syndrome
Lemche, E., Чабан, О., & Lemche, A. V. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00142 · Cited by 50
ACTH Antagonists
Clark, A. J., Forfar, R., Hussain, M., Jerman, J., McIver, E., Taylor, D., & Chan, L. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00101 · Cited by 49
“Substantial efforts have been made to develop small molecules as agonists of the MC4 receptor with some limited success (61).”
Background
MECHANISMS IN ENDOCRINOLOGY: Update on treatments for patients with genetic obesity
Poitou, C., Mosbah, H., & Clément, K. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0363 · Cited by 46
The central melanocortin system and human obesity
Yang, Y., & Xu, Y. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa048 · Cited by 48
Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity
Trapp, C. M., & Censani, M. (2023) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000798 · Cited by 41
“Published by Wolters Kluwe show clinical efficacy and/or had undesirable adverse effect profiles [7,8].”
Background
Neurotransmitters in Type 2 Diabetes and the Control of Systemic and Central Energy Balance
Al-Sayyar, A., Hammad, M. M., Williams, M. R., Al‐Onaizi, M., Abubaker, J. A., & Alzaïd, F. (2023) · Metabolites · doi:10.3390/metabo13030384 · Cited by 45
Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges
Brandfon, S., Eylon, A., Khanna, D., & Parmar, M. S. (2023) · Cureus · doi:10.7759/cureus.46623 · Cited by 40
Melanocortin-4 Receptor Gene Variation Is Associated with Eating Behavior in Chilean Adults
Vega, J. A., Salazar, G., Hodgson, M. I., Cataldo, L. R., Valladares, M., Obregón, A. M., & Santos, J. L. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000439092 · Cited by 38
ACGCN: Graph Convolutional Networks for Activity Cliff Prediction between Matched Molecular Pairs
Park, J., Sung, G., Lee, S., Kang, S., & Park, C. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00327 · Cited by 39
Naturally occurring mutations in G protein-coupled receptors associated with obesity and type 2 diabetes mellitus
Liu, T., Ji, R.-L., & Tao, Y.-X. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108044 · Cited by 34
MC4R Variant rs17782313 Associates With Increased Levels of DNAJC27, Ghrelin, and Visfatin and Correlates With Obesity and Hypertension in a Kuwaiti Cohort
Hammad, M. M., Abu‐Farha, M., Hebbar, P., Cherian, P., Khairi, I. A., Melhem, M., Alkayal, F., Alsmadi, O. A., Thanaraj, T. A., Al‐Mulla, F., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00437 · Cited by 39
The Use of Amphipols for NMR Structural Characterization of 7-TM Proteins
Elter, S., Raschle, T., Arens, S., Viegas, A., Gelev, V., Etzkorn, M., & Wagner, G. (2014) · The Journal of Membrane Biology · doi:10.1007/s00232-014-9669-5 · Cited by 32
Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach
Falls, B. A., & Zhang, Y. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00346 · Cited by 29
Pharmacogenetic Correlates of Antipsychotic-Induced Weight Gain in the Chinese Population
Luo, C., Liu, J., Wang, X., Mao, X., Zhou, H., & Liu, Z. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-018-0323-6 · Cited by 31
Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary
Raskin, P., & Cincotta, A. H. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1131119 · Cited by 28
Sex and gender differences in cardiovascular, renal and metabolic diseases
Reckelhoff, J. F., & Samson, W. K. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00417.2015 · Cited by 27
Nutrigenetics and nutrigenomics—A personalized approach to nutrition
Ahluwalia, M. K. (2021) · Advances in genetics · doi:10.1016/bs.adgen.2021.08.005 · Cited by 27
Obesity‐associated mutant melanocortin‐4 receptors with normal Gαs coupling frequently exhibit other discoverable pharmacological and biochemical defects
Gillyard, T. R., Fowler, K., Williams, S. Y., & Cone, R. D. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12795 · Cited by 26
Structural Complexity and Plasticity of Signaling Regulation at the Melanocortin-4 Receptor
Kleinau, G., Heyder, N., Tao, Y., & Scheerer, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165728 · Cited by 30
The role of food intake regulating peptides in cardiovascular regulation
Mikulášková, B., Maletı́nská, L., Zicha, J., & Kuneš, J. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.07.021 · Cited by 25
MC4R Variants Modulate α-MSH and Setmelanotide Induced Cellular Signaling at Multiple Levels
Rondon, A. V. R., Welling, M. S., van den Akker, E. L. T., van Rossum, E. F. C., Boon, E. M. J., van Haelst, M. M., Delhanty, P. J. D., & Visser, J. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae210 · Cited by 18
Brain fractalkine-CX3CR1 signalling is anti-obesity system as anorexigenic and anti-inflammatory actions in diet-induced obese mice
Kawamura, N., Katsuura, G., Yamada-Goto, N., Nakama, R., Kambe, Y., Miyata, A., Furuyashiki, T., Narumiya, S., Ogawa, Y., & Inui, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-16944-3 · Cited by 20
Natural Products-Based Pancreatic Lipase Inhibitors for Obesity Treatment
Sridhar, S. N. C., George, G., Verma, A., & Paul, A. T. (2019) · Springer eBooks · doi:10.1007/978-981-13-7154-7_6 · Cited by 19
Network dynamics of hypothalamic feeding neurons
Sweeney, P., Chen, C., Rajapakse, I., & Cone, R. D. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2011140118 · Cited by 19
From Mother to Child: Epigenetic Signatures of Hyperglycemia and Obesity during Pregnancy
Franzago, M., Borrelli, P., Di Nicola, M., Cavallo, P., D’Adamo, E., Di Tizio, L., Gazzolo, D., Stuppia, L., & Vitacolonna, E. (2024) · Nutrients · doi:10.3390/nu16203502 · Cited by 18
The Role of Proopiomelanocortin and α-Melanocyte-Stimulating Hormone in the Metabolic Syndrome in Psychiatric Disorders: A Narrative Mini-Review
Raue, S., Wedekind, D., Wiltfang, J., & Schmidt, U. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00834 · Cited by 17
Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials
Spana, C., Jordan, R., & Fischkoff, S. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14672 · Cited by 15
Turning the clock forward: New pharmacological and non pharmacological targets for the treatment of obesity
Ferrulli, A., Terruzzi, I., Senesi, P., Succi, M., Cannavaro, D., & Luzi, L. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.02.016 · Cited by 17
The Role of the Melanocortin System in Drug and Alcohol Abuse
Navarro, M. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.06.009 · Cited by 16
Aqueous remote loading of setmelanotide in poly(lactic-co-glycolic acid) microspheres for long-term obesity treatment
Wang, S., Downing, G., Olsen, K. F., Sawyer, T. K., Cone, R. D., & Schwendeman, S. P. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.015 · Cited by 15
Eating behaviour in contrasting adiposity phenotypes: Monogenic obesity and congenital generalized lipodystrophy
Santos, J. L., & Cortés, V. (2020) · Obesity Reviews · doi:10.1111/obr.13114 · Cited by 19
High Cortisol Response to Adrenocorticotrophic Hormone Identifies Ewes with Reduced Melanocortin Signalling and Increased Propensity to Obesity
Hewagalamulage, S. D., Clarke, I. J., Young, I. R., Rao, A., & Henry, B. A. (2014) · Journal of Neuroendocrinology · doi:10.1111/jne.12233 · Cited by 15
A look on food intake and satiety: from humans to rodent models
Costa, D. G., Almeida, C., Cavadas, C., & Carmo‐Silva, S. (2022) · Nutrition Reviews · doi:10.1093/nutrit/nuac010 · Cited by 17
Mutations in melanocortin-4 receptor: From fish to men
Tao, Y. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.03.003 · Cited by 14
MC4R biased signalling and the conformational basis of biological function selections
Liu, Z., & Hruby, V. J. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17441 · Cited by 15
Developments and new vistas in the field of melanocortins
Leone, S., Noera, G., & Bertolini, A. (2015) · BioMolecular Concepts · doi:10.1515/bmc-2015-0023 · Cited by 13
Structural Analysis of Setmelanotide Binding to MC4R Variants in Comparison to Wild-Type Receptor
Hammad, M. M., Mohammad, A., Alam-Eldin, N., Madhu, D., Al‐Mulla, F., Abu‐Farha, M., & Abubaker, J. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120857 · Cited by 12
Melanocortin-4 receptors activate sympathetic preganglionic neurons and elevate blood pressure via TRPV1
Ju, S. H., Yun, H., Oh, Y., Choi, Y., & Sohn, J. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111579 · Cited by 11
Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy
Merlino, D. J., Blomain, E. S., Aing, A., & Waldman, S. A. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030763 · Cited by 13
The Obesogenic Environment: Epigenetic Modifications in Placental Melanocortin 4 Receptor Gene Connected to Gestational Diabetes and Smoking
Franzago, M., Porreca, A., D’Ardes, M., Nicola, M. D., Tizio, L. D., Liberati, M., Stuppia, L., & Vitacolonna, E. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.879526 · Cited by 11
Hindbrain melanocortin 3/4 receptors modulate the food intake and body weight suppressive effects of the GLP-1 receptor agonist, liraglutide
Fortin, S. M., Chen, J., & Hayes, M. R. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.112870 · Cited by 10
Pharmacological effects of fibroblast growth factor 21 are sex-specific in mice with the lethal yellow (Ay) mutation
En, M., Yakovleva, T. V., Balybina, N., Baranov, K. O., Denisova, E. I., Dubinina, A., Feofanova, N. A., & Бажан, Н. М. (2020) · Vavilov Journal of Genetics and Breeding · doi:10.18699/vj20.40-o · Cited by 10
Melanocortin-4 Receptor Modulators for the Treatment of Obesity: a Patent Analysis (2008–2014)
Lee, E. C. Y., & Carpino, P. A. (2015) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.15.1 · Cited by 10
Metabolomics Reveals the Alteration of Metabolic Pathway by Alpha-Melanocyte-Stimulating Hormone in B16F10 Melanoma Cells
Seo, S.-H., Jo, J. K., Kim, E.-J., Park, S., Shin, S. Y., Park, K. M., & Son, H.-S. (2020) · Molecules · doi:10.3390/molecules25153384 · Cited by 9
Prevalence of POMC R236G mutation in Pakistan
Shabana, N. A., & Hasnain, S. (2015) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2015.10.007 · Cited by 8
Solution structure of the transmembrane 2 domain of the human melanocortin-4 receptor in sodium dodecyl sulfate (SDS) micelles and the functional implication of the D90N mutant
Yun, J.-H., Kim, M., Kim, K., Lee, D., Jung, Y., Oh, D.-S., Ko, Y., Cho, A. E., Cho, H., & Lee, W. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2015.02.029 · Cited by 8
New Thoughts on Pediatric Genetic Obesity: Pathogenesis, Clinical Characteristics and Treatment Approach
Stagi, S., Bianconi, M., Sammarco, M. A., Artuso, R., Giglio, S., & de Martino, M. (2017) · InTech eBooks · doi:10.5772/66128 · Cited by 7
Role of Obesity in Human Health and Disease
Rao, V., & Rao, L. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.90990 · Cited by 8
An effect of dietary phloretin supplementation on feed intake in mice
Xu, X., Chen, X., Huang, Z., Chen, D., Yu, B., Chen, H., Zheng, P., Luo, Y., & Yu, J. (2019) · Food & Function · doi:10.1039/c9fo00815b · Cited by 8
The Multiple Causes of Obesity
Saxena, I., Suman, S., Kaur, A. P., Abhilasha, Mitra, P., Sharma, P., & Kumar, M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98835 · Cited by 8
Antiobesity Pharmacotherapy for Patients With Genetic Obesity Due to Defects in the Leptin-Melanocortin Pathway
Welling, M. S., van Rossum, E. F. C., & van den Akker, E. L. T. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf004 · Cited by 6
Melanocortins and Their Potential for the Treatment, Prevention and Amelioration of Complications of Diabetes
Robinson, G. N., & Pickering, R. J. (2024) · Diabetology · doi:10.3390/diabetology5010006 · Cited by 6
Melanocortin-4 Receptor Deficiency Phenotype with an Interstitial 18q Deletion: A Case Report of Severe Childhood Obesity and Tall Stature
Abdullah, S., Reginold, W., Kiss, C., Harrison, K. J., & MacKenzie, J. J. (2016) · Case Reports in Pediatrics · doi:10.1155/2016/6123150 · Cited by 6
New Perspectives on the Development of Antiobesity Drugs
Costantino, L., & Barlocco, D. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.167 · Cited by 5
Cyclotides in a Biotechnological Context
Jackson, M. A., & Gilding, E. K. (2015) · Advances in botanical research · doi:10.1016/bs.abr.2015.09.010 · Cited by 5
Structural Insight into the MC4R Conformational Changes via Different Agonist-Mediated Receptor Signaling
Yang, Y., Chen, M., Dimmitt, R. A., & Harmon, C. M. (2014) · Biochemistry · doi:10.1021/bi500856x · Cited by 5
The melanocortin system as a potential target for treating alcohol use disorders: A review of pre-clinical data
Lerma-Cabrera, J. M., Carvajal, F., Garbutt, J. C., Navarro, M., & Thiele, T. E. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146628 · Cited by 4
Genetics of Obesity
Dubern, B., Clément, K., & Poitou, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48559-3.00014-2 · Cited by 3
Current pharmacological approaches in obesity treatment
TİRYAKİOĞLU, P., Yilmaz, H., Demir, İ., & Yilmaz, I. C. (2023) · DAHUDER Medical Journal · doi:10.56016/dahudermj.1271677 · Cited by 4
KNIME-based Analysis of Off-Target Effect of Drugs Related to The Molecular 2D Fingerprint
Karimah, N., & Schaftenaar, G. (2021) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps31771 · Cited by 2
From a Cone Snail Toxin to a Competitive MC4R Antagonist
Reynaud, S., Laurin, S., Ciolek, J., Barbe, P., van Baelen, A.-C., Susset, M., Blondel, F., Ghazarian, M., Boeri, J., Driessche, M. V., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00786 · Cited by 2
Alvos moleculares dos fármacos utilizados na perda de peso dos pacientes com obesidade
Santana, G. S., dos Reis, M. R., Santos, M. D. S., Costa, L. Q. S., de Franca, M. N. F., de Almeida, G. K. M., Seabra, M. S. D. M., & Souza, M. T. D. S. (2025) · Cuadernos de Educación y Desarrollo · doi:10.55905/cuadv17n1-067 · Cited by 2
Dolutegravir-induced growth and lifespan effects in Caenorhabditis elegans
Kuo, S., Hsu, W., Wu, C., Lai, Y., & Chen, T. (2023) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-023-00715-5 · Cited by 2
Récepteur MC4R : actualités de la recherche dans l’obésité et potentiels développements thérapeutiques
Duquesnoy, M., Mosbah, H., Clément, K., Dubern, B., & Poitou, C. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.07.002 · Cited by 1
The effect of melanocortin-4 receptor agonist drugs on obesity and metabolic risk factors: a systematic review and meta-analysis
Sun, Y., Abed, M., & Sohouli, M. H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02071-2 · Cited by 1
Co-expression of human agouti-related protein enhances expression and stability of human melanocortin-4 receptor
Yun, J.-H., Kim, K., Jung, Y., Park, J.-H., Cho, H., & Lee, W. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.11.044 · Cited by 1
IV. Relation of NAFLD with Lifestyle-related Disease Including Obesity, Dyslipidemia and Hypertension
Kogiso, T. (2016) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.105.31 · Cited by 1
Monogene Adipositas (Melanocortin-4-Rezeptor-Mangel)
Baumgartner-Parzer, S. M. (2018) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-018-0039-2 · Cited by 1
Nutrigenomics Approaches to Control Metabolic Diseases and Challenges to Personalized Nutritional Intervention
Singh, C., Sharma, A., Bishnoi, M., Kondepudi, K. K., & Singh, R. P. (2020) · Springer eBooks · doi:10.1007/978-981-15-2874-3_12 · Cited by 1
Familial early-onset obesity in Turkish children: variants and polymorphisms in the melanocortin-4 receptor (MC4R) gene
Kırmızıbekmez, H., Demirkol, Y. K., Doğan, Ö. A., Karabulut, G. S., Balcı, E. İ., Atla, P., & Dursun, F. (2022) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2021-0756 · Cited by 1
Approved Protein Therapeutics and Their Biochemical Targets
Ramesh, R., & Ravichandran, R. (2023) · Springer eBooks · doi:10.1007/978-981-19-8249-1_7 · Cited by 1
Diabesity and the Kidney
Elrggal, M. E., Elkeraie, A. F., Carriazo, S. M., Sawaf, H., Khor, S. Y., Elkeraie, Y., Haddad, I. R., Moustafa, K., & Hassanein, M. M. (2023) · Frontiers in clinical drug research. Diabetes and obesity · doi:10.2174/9789815123586123070009 · Cited by 1
Obesity and Stress: The Melanocortin Connection
Singhal, S., & Hill, J. W. (2018) · Springer eBooks · doi:10.1007/978-3-319-89506-2_11 · Cited by 1
Central Modulators of Appetite in Eating Disorders
Procházková, P., Roubalová, R., & Papežová, H. (2023) · Springer eBooks · doi:10.1007/978-3-030-97416-9_112-1 · Cited by 1
Novo sets sights on obesity market with diabetes drug
Sheridan, C. (2014) · Nature Biotechnology · doi:10.1038/nbt1114-1071

Authors: Fani, L., Bak, S., Delhanty, P., van Rossum, E. F. C., & van den Akker, E. L. T.
Affiliations: Erasmus MC (NL)
ORCID: Fani, L
Delhanty, P
Venue: International Journal of Obesity
Publisher: Springer Science and Business Media LLC
Published: 2013-06-18
Volume: 38
Issue: 2
Pages: 163-169
ISSN: 0307-0565 (ISSN-L)
1476-5497
DOI: 10.1038/ijo.2013.80
OpenAlex: W2019132602
Cited by: 121
References: 33
Citations by year: 2025: 4 · 2024: 4 · 2023: 20 · 2022: 15 · 2021: 6 · 2020: 13 · 2019: 9 · 2018: 6 · 2017: 7 · 2016: 12 · 2015: 16 · 2014: 8 · 2013: 1
FWCI: 1.49
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: International Journal of Obesity (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Topics: Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords: melanocortin-4 receptor, obesity treatment, MC4R agonist, appetite regulation, energy homeostasis, satiety, body weight regulation, pharmacotherapy
MeSH terms: Acetamides, alpha-MSH, Animals, Appetite Regulation, Energy Intake, Energy Metabolism, Gene Frequency, Genotype, Humans, Obesity, Peptides, Cyclic, Phenotype, Pyrrolidines, Receptors, Cell Surface, Spiro Compounds, Body Mass Index, Anti-Obesity Agents, Receptor, Melanocortin, Type 4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks